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	 Objective	 The fetal fibronectin test is advocated to facilitate the 
management of women presenting with threatened preterm 
labour, but is underutilised in Hong Kong. This study aimed to 
provide experience with this test and evaluate its utility in a local 
setting.
	 Design	 Prospective cohort study.
	 Setting	 A university-affiliated hospital in Hong Kong.
	 Patients	 Women presenting with symptoms of preterm labour were 
recruited from 1 January 2011 to 30 June 2012.
	Main	outcome	measures	 The sensitivity, specificity, positive predictive value, and negative 
predictive value of the fetal fibronectin test to predict delivery 
within 24 hours, 48 hours, 7 days, and 14 days.
 Results A total of 22 women were recruited; 12 (55%) of whom had a 
negative fetal fibronectin test, none of whom delivered within 
7 days; six received corticosteroids and tocolysis, one of whom 
delivered within 14 days. The 10 remaining women had a positive 
fetal fibronectin test. Five of whom delivered within 7 days and 
two within 14 days; all of them had received corticosteroids and 
tocolysis. For predicting delivery within 7 days, the sensitivity and 
negative predictive value of the test were both 100%.
	 Conclusions	 Our study demonstrated the high negative predictive value of 
the fetal fibronectin test in our local setting, which suggests that 
it should be utilised more readily in women presenting with 
threatened preterm labour.
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Introduction
Preterm birth is a major challenge to perinatal health. It accounts for 75% of perinatal 
deaths and more than 50% of long-term neurological disabilities.1,2 The frequency of 
preterm births is increasing worldwide, due to the use of assisted reproductive techniques 
coupled with the increasing frequency of multiple pregnancies.1,2
 The traditional approach to predicting preterm labour was to identify risk factors, 
detect persistent uterine contractions, and look for progressive cervical dilatation and 
effacement. However, most women do not have risk factors. Moreover, only about 10% 
of spontaneous early preterm births are associated with a history of prior preterm labour, 
and the symptoms and signs that ensue are often vague and non-specific.3,4 Because of 
the poor sensitivity and positive predictive value (PPV) of symptoms and signs of preterm 
labour, early detection has been difficult. Hence, both overdiagnosis and early initiation 
of tocolysis and corticosteroids are common. Recent studies have shown that repeated 
courses of corticosteroids are associated with decreased weight, length, and head 
circumference of the fetus at birth,5 and tocolysis also has adverse effects. Therefore, 
tocolytics and corticosteroids should be used with caution.6
New	knowledge	added	by	this	study
• The negative predictive values of the fetal fibronectin test for delivery within 24 hours, 48 
hours, and 7 days were 100%.
• A positive fetal fibronectin test is associated with delivery within 24 hours, 48 hours, 7 days, 14 
days, and before 34 weeks and 37 weeks.
Implications	for	clinical	practice	or	policy
• The fetal fibronectin test should be utilised to facilitate the obstetric management of women 
presenting with threatened preterm labour.
ONLINE FIRST
DOI: 10.12809/hkmj133861
This article was published on  
22 April 2013 at <www.hkmj.org>.
This version may differ from the 
print version.
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 The prediction of preterm birth is challenging. 
In recent years, the fetal fibronectin (FFN) test has 
been used to predict preterm labour. Fetal fibronectin 
is a glycoprotein found in the extracellular substance 
of the decidua basalis next to the placental intervillous 
space.7 It is localised between the chorion and decidua. 
The obliteration of the extra-amniotic space, and close 
approximation of the chorion and decidual surface 
results in disappearance of FFN in vaginal secretions 
from 20 weeks of gestation onwards. Detection of 
FFN in vaginal secretions thereafter may therefore 
represent pathological disruption of the maternal 
fetal interface and help to indicate genuine preterm 
birth. Due to its high negative predictive value (NPV), 
a negative test therefore helps to predict symptomatic 
women who will not deliver within 7 days.7-9 
 The use of the FFN test for the management 
of women with symptoms of preterm labour 
is recommended by the American College 
of Obstetricians and Gynecologists10 and the 
Royal Australian and New Zealand College of 
Obstetricians and Gynaecologists.11 However, the 
test is underutilised in Hong Kong and local data 
are lacking. We therefore conducted a pilot study to 
provide experience and evaluate the accuracy of the 
test in a local setting. Our objective was to determine 
the sensitivity, specificity, PPV, and NPV of the FFN 
test as a predictor of delivery within 24 hours, 48 
hours, 7 days, and 14 days.
 目的 胎兒纖連蛋白測試可用於預測早產風險，從而加強對
產婦的護理，可惜這測試在香港並未得到充分利用。
本研究旨在分享使用胎兒纖連蛋白測試的經驗，以及
評估胎兒纖連蛋白測試在本地運用的準確性。
 設計 前瞻性隊列研究。
 安排 香港一所大學的附屬醫院。
 患者 2011年1月1日至2012年6月30日期間出現早產症狀的
婦女。
 主要結果測量 胎兒纖連蛋白測試於24小時、48小時、7天及14天預
測分娩的敏感性、特異性、陽性預測值和陰性預測
值。
 結果 22名參與研究的婦女中，12人（55%）的胎兒纖連蛋
白測試結果呈陰性，沒有人在7天內分娩；6人使用
皮質類固醇及子宮收縮抑制劑，其中1人在14天內分
娩。餘下10人的胎兒纖連蛋白測試結果呈陽性。5人
在7天內分娩，2人在14天內分娩，全部曾使用皮質類
固醇及子宮收縮抑制劑。胎兒纖連蛋白測試對於預測
7天內分娩的敏感度和陰性預測值均為100%。
 結論 本研究顯示胎兒纖連蛋白測試在本地有高陰性預測
值，可應用於有早產症狀的產婦。
替有早產症狀的華籍產婦進行胎兒纖連蛋白測試
的先導研究
Methods
This was a prospective observational study 
conducted between 1 January 2011 and 30 June 2012 
in the Department of Obstetrics and Gynaecology of 
Queen Mary Hospital, Hong Kong. Chinese women 
with gestational ages of 24+0 to 33+6 weeks, who 
presented with symptoms or signs of threatened 
preterm labour, were studied. Threatened preterm 
labour was defined as uterine contractions detected 
by the tocodynamometry with symptoms of 
abdominal pain or vaginal bleeding before term. 
Women were given an information sheet about the 
study and the use of the FFN test. Inclusion criteria 
were age of ≥18 years, with more than six contractions 
per hour by external tocodynamometry and cervical 
dilatation of ≤3 cm. Women were excluded if they 
had premature rupture of membranes, triplet or 
greater number of pregnancies, a prior fetal FFN test 
performed elsewhere, prior cervical examination 
or sexual intercourse within 24 hours, a history of 
prior tocolysis, moderate or heavy vaginal bleeding, 
cervical cerclage, placenta praevia, or known 
congenital anomaly of their fetus. All women gave 
written informed consent and were enrolled under 
protocols approved by the Institutional Review Board 
of The University of Hong Kong/Hospital Authority 
Hong Kong West Cluster.
 Gestational age was calculated from the 
first day of the last normal menstrual period and 
confirmed by ultrasonographic measurements in 
the first or second trimester. For women in whom 
there was a discrepancy (the last menstrual period 
and ultrasound-based gestational age difference was 
≥7 days at <14 weeks, or ≥14 days at 14-24 weeks), 
gestational age was based on measurements obtained 
at the initial ultrasound examination.
 During the gynaecological examination, a 
speculum using water as lubricant was introduced 
into the vagina before any digital or transvaginal 
ultrasound examination. Testing for rupture of 
membranes was performed by observing pooling 
of liquor in the posterior fornix, and asking the 
women to cough to observe any leakage through the 
cervical os. A polyester swab was inserted into the 
posterior fornix and rotated for 10 seconds to absorb 
cervicovaginal secretions. The swab was placed into 
the collection tube provided and the FFN test was 
analysed with TLiQ (FullTerm) [Hologic, Marlborough, 
US]. The result was either positive or negative, using 
50 ng/mL as the cut-off. The test result was concealed 
from the women and the attending physician. 
Management was at the discretion of the attending 
physician. Quantitative data were expressed as 
means and standard deviations. Data were analysed 
using Student’s t test for continuous variables which 
were normally distributed and the Mann-Whitney 
U test for skewed data. The Chi squared or Fisher’s 
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exact tests were used for dichotomous outcomes. A P 
value of <0.05 was considered statistically significant.
Results
In all, 25 women were considered suitable during 
the study period, but two refused and one was 
excluded because of a fetal congenital cardiac 
abnormality, leaving 22 women who were suitable 
and agreed to participate. The maternal demographic 
characteristics of these patients are shown in Table 1; 
20 were singleton and 2 were twin pregnancies. 
 There were significantly more women with a 
positive FFN test who presented with vaginal bleeding 
(P=0.001). Overall, nine (41%) presented with vaginal 
bleeding, of which seven also had abdominal pain. 
Of eight women who had vaginal bleeding and 
a positive FFN test, one had placental abruption 
and delivered vaginally within 24 hours of FFN test, 
and one had a show and delivered within 24 hours. 
Three others had an antepartum haemorrhage of 
unknown origin and delivered within 7 days, 14 days, 
and at term. Another three had caesarean deliveries 
(one at 31 weeks for breech presentation following 
a preterm labour with the cervix dilated to 5 cm 
within 24 hours; one within 24 hours at 31 weeks for 
placental abruption and a twin pregnancy; one at 34 
weeks for preterm prelabour rupture of membranes 
and a twin pregnancy 10 days after FFN test). The 
remaining woman who had vaginal bleeding and a 
negative FFN test had an antepartum haemorrhage of 
unknown origin and delivered at term.
 The FFN test results and the delivery outcomes 
are listed in Table 2. A total of 12 (55%) of the women 
had negative FFN tests; none delivered within 7 days, 
six of whom received corticosteroid and tocolysis, 
of which one delivered within 14 days. Regarding 
the 10  women (45% of those tested) who had 
positive FFN tests, five delivered within 7 days and 
two more within the next 7 days; all of them had 
received corticosteroids and tocolysis; the remaining 
three women received conservative management 
and delivered at term. Having a positive FFN was 
associated with delivery within 24 hours, 48 hours, 7 
days, 14 days, before 34 weeks, and 37 weeks (P<0.05). 
The test’s sensitivity and NPV were 100% to predict 
delivery within 7 days (Table 3). The sensitivity and 
NPV remained 100% to predict delivery within 7 
days even if two cases with twin pregnancies were 
excluded. Both women with twin pregnancies 
presented with abdominal tightening and vaginal 
bleeding. They had a positive FFN test and were 
delivered for an obstetric indication. One delivered 
at 31 weeks and 3 days for placental abruption within 
24 hours of the FFN test. The other delivered at 34 
weeks and 3 days for preterm prelabour rupture of 
membranes 10 days after the FFN test. 
Discussion
In previous studies, the NPV of the FFN test for 
delivery within 7 days was 99 to 99.5%.8,9 Our results 
confirmed the high NPV of the test to predict preterm 
delivery. Honest et al7 reviewed 40 studies on the 
accuracy of the FFN test in symptomatic women. 
The likelihood ratio for a positive test was 5.4 (95% 
confidence interval [CI], 4.4-6.7) for birth within 7 to 
10 days, with a corresponding likelihood ratio for a 
negative test of 0.25 (95% CI, 0.20-0.31).7 In the current 
study, the likelihood ratio for a positive and negative 
FFN test for delivery within 7 days were 3.4 (95% CI, 
1.6-7.1) and 0.0, respectively. 
 In our study, significantly more women 
presenting with vaginal bleeding had positive rather 
than negative FFN tests (8 vs 1, P=0.001); five (63%) 
of those with positive tests delivered within 7 days. 
Although vaginal bleeding may be related with 
preterm delivery, the presence of blood in the vagina 
may be associated with a false-positive FFN test.12 
TABLE 1.  Maternal demographic characteristics
Characteristic Mean ± standard deviation or No. P value
FFN* positive 
(n=10)
FFN negative 
(n=12)
Age (years) 33.3 ± 3.1 31.5 ± 3.4 0.259
Nulliparous 6 10 0.221
History of preterm labour 2 0 0.104
Gestational age at recruitment 
(weeks) 
30.5 ± 3.2 29.1 ± 3.3 0.210
Symptoms
Vaginal bleeding 8 1 0.001
Abdominal pain 8 12 0.104
TABLE 2.  Fetal fibronectin (FFN) test results and delivery outcomes
Delivery outcome Mean ± standard deviation or No. P value
FFN positive 
(n=10)
FFN negative 
(n=12)
Gestational age at delivery (weeks) 34.1 ± 3.5 38.5 ± 2.0 0.008
Mode of delivery* 0.452
Vaginal 6 (4) 9 (2)
Caesarean section 4 (3) 3 (0)
Delivery 
<24 Hours 4 0 0.015
<48 Hours 4 0 0.015
<7 Days 5 0 0.005
<14 Days 7 1 0.003
<34 Weeks 5 1 0.029
<37 Weeks 7 2 0.011
Use of tocolysis 7 6 0.342
Use of corticosteroids 7 6 0.342
Duration of hospital stay (days) 3.8 ± 1.8 3.7 ± 1.7 0.812
* The No. of cases delivering before 37 weeks are shown in brackets
* FFN denotes fetal fibronectin
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 The clinical utility of the FFN test relates to its 
high NPV to identify women who were at low risk of 
preterm delivery. It may avoid unnecessary hospital 
admissions, prolonged hospital stays, transferal to 
tertiary units with advanced neonatal support, and the 
administration of tocolysis and corticosteroids. Based 
on the high NPV for delivery within 7 days, in our 
study tocolysis and corticosteroids could be withheld 
in women with a negative FFN test and reassessment 
considered after 7 days. Women with a positive FFN 
should be considered for receipt of corticosteroids 
and tocolysis. Dutta and Norman13 reviewed the 
efficacy of the FFN test in hospital admissions, from 
the perspective of length of hospital stay and cost 
savings. They detailed seven studies demonstrating a 
correlation of FFN test results with an actual estimate 
of health care cost savings, especially in women 
with a negative FFN test.13 Although observational 
studies suggested that the FFN test may be useful, no 
randomised study evaluating its use has demonstrated 
a clear benefit.14-17 
 Grobman et al14 randomised 100 symptomatic 
women to having an available FFN result and another 
group without such information. There was no 
difference in the number of hospital admission, use 
of tocolysis and corticosteroids, patient perceptions 
or total medical and non-medical costs.14 Lowe 
et al15 and Plaut et al16 randomised 97 and 100 
patients respectively using a similar methodology, 
to evaluate whether an available FFN result would 
affect management, and found no difference in the 
use of betamethasone, tocolysis, and antibiotics, 
but did find fewer admissions in women with a 
negative rather than positive FFN test result. Lowe 
et al15 also encountered shorter hospital stays, but 
no such difference was found by Plaut et al.16 Ness 
et al17 randomised 100 women; one group had the 
transvaginal cervical length (TVCL) and results of 
any FFN test made available to them, and another 
group was not given such information. Those with 
TVCLs of <20 mm underwent further treatment at 
the physician’s discretion while those with TVCLs 
of >30 mm could be discharged. The FFN test was 
performed in women with TVCLs of 20 to 29 mm. The 
availability of such a result was not associated with 
a shorter interval between evaluation and discharge. 
However, having such information was associated 
with an increased admission rate. Vis et al18 reviewed 
the four above-mentioned randomised controlled 
trials and found that the absence of a beneficial 
clinical effect was largely related to the methodology. 
No fixed management protocol was used and the 
management of threatened preterm labour was left to 
the discretion of the treating physician, irrespective of 
the FFN result. Physician could still treat the women 
as ‘high-risk’ despite a negative FFN test. Accordingly, 
a randomised controlled trial using a fixed protocol 
with negative FFN test results is needed to evaluate 
the true clinical benefit and cost-effectiveness of the 
test.
 The FFN test is easy to perform, whereas a 
transvaginal ultrasound scan for cervical length is 
technically demanding, operator-dependent, and 
can be time-consuming. Thus, the FFN test could be 
helpful in women with undetermined TVCLs. Hincz et 
al19 suggested using the test in women with TVCLs of 
21 to 31 mm. With this sequential combined approach, 
the sensitivity and NPV to predict delivery within 28 
days increased to 86% and 97%, respectively.19 Gomez 
et al20 also suggested adding the FFN test to improve 
the prediction of preterm delivery when the TVCL 
is <30 mm. The FFN test is currently underutilised 
in public and private hospitals in Hong Kong. 
Obstetricians may prefer resorting to the TVCL, 
which provides another effective means of evaluating 
women with symptoms of preterm labour. Although 
TVCL requires expertise, there is an accreditation 
programme offered by the Fetal Medicine Foundation 
in the United Kingdom, which can be easily accessed 
through the internet (http://www.fetalmedicine.
com/fmf/online-education/05-cervical-assessment/). 
Currently, ultrasonography is easily available for 
obstetricians, and TVCL can be readily available after 
the examination, with no additional cost. Shortening 
of the cervix is a strong predictor of preterm labour. 
Serial TVCL measurements could allow comparison 
with previous measurements; any change could 
provide obstetricians and women more information, 
and facilitate counselling and subsequent 
management. On the other hand, the FFN bedside 
kit is not widely available in Hong Kong; obstetricians 
need to wait around 30 minutes for a result, and each 
test entails an extra cost. Its NPV is useful when it 
comes to facilitating further obstetric management, 
TABLE 3.  The accuracy of fetal fibronectin tests*
<24 Hours <48 Hours <7 Days <14 Days <34 Weeks <37 Weeks
Sensitivity (%) 100 (45.4-100) 100 (45.4-100) 100 (47.8-100) 87.5 (47.3-99.6) 83.3 (35.8-99.5) 77.8 (39.9-97.1)
Specificity (%) 66.6 (40.9-86.6) 66.6 (40.9-86.6) 70.1 (44.0-89.6) 78.6 (49.2-95.3) 68.8 (41.3-88.9) 76.9 (46.1-94.9)
PPV† (%) 40 (12.1-73.7) 40 (12.1-73.7) 50 (18.7-81.2) 70 (34.7-93.3) 50 (18.7-81.2) 70 (34.7-93.3)
NPV‡ (%) 100 (73.5-100) 100 (73.5-100) 100 (73.5-100) 91.7 (61.5-99.7) 91.7 (61.5-99.7) 83.3 (51.5-97.9
* 95% Confidence intervals are shown in brackets
† PPV denotes positive predictive value
‡ NPV denotes negative predictive value
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but a positive result may not help. A false-positive 
FFN test can be due to prior sexual intercourse or 
cervical examination within 24 hours, which hinders 
its use in these situations. The limited PPV of the 
test may also lead to unnecessary treatment and 
maternal anxiety in low-risk patients. Another reason 
for underutilisation of the FFN test could be lack of 
familiarity, and worry about false-negative results 
leading to a preterm birth without corticosteroid 
protection. The legal liability environment may also 
influence the behaviour of obstetricians, leading to 
over-treatment rather than relying on the FFN result. 
Our study showed the NPV for delivery within 24 
hours, 48 hours, and 7 days were 100%, which should 
offer confidence to the local doctors and support its 
use to manage women who present with threatened 
preterm labour.
 The main limitation of this study was the small 
sample size. Nevertheless, our results showing 
a high NPV were consistent with reports in the 
published literature.8,9 The importance of this study 
is that it can increase awareness of the FFN test in 
Hong Kong and offer confidence to apply the test 
in clinical settings. Adherence to an agreed local 
protocol especially with a negative FFN result is 
critical. A second limitation was the inclusion of 
women with vaginal bleeding but without abdominal 
pain. Although uterine contractions were detected 
on tocodynamometry, this may represent Braxton 
Hicks contractions, rather than genuine preterm 
labour. Nevertheless, a negative FFN test may still be 
useful by offering attending physicians confidence 
to adopt conservative management. As management 
with FFN testing may not be beneficial without a 
fixed protocol, further randomised controlled trials 
addressing this issue may achieve better evaluation 
of the test’s clinical benefit. 
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